<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01513161</url>
  </required_header>
  <id_info>
    <org_study_id>TRK-820_PRU_III_2007</org_study_id>
    <nct_id>NCT01513161</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of TRK-820 to Treat Conventional-treatment-resistant Pruritus in Patients Receiving Hemodialysis</brief_title>
  <acronym>TRK-820</acronym>
  <official_title>A 14 Day, Multi-center, Randomized, Double Blinded, Placebo-controlled, Parallel Group, Fixed Dose, Phase III Clinical Trial to Assess the Efficacy and Safety of TRK-820 in Treating Conventional-treatment-resistant Pruritus in Patients Receiving Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SK Chemicals Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Toray Industries, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>SK Chemicals Co.,Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether nalfurafine hydrochloride is effective and
      safe in the treatment for conventional-treatment-resistant pruritus in patients receiving
      hemodialysis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in pruritus degree measured by VAS(Visual Analogue Scale) score</measure>
    <time_frame>4 weeks (2 weeks measurement with only conventional treatment + 2 weeks measurement with conventional treatment &amp; investigational products)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Shiratori's severity scores assessed by the subject.</measure>
    <time_frame>4 weeks (2 weeks measurement with only conventional treatment + 2 weeks measurement with conventional treatment &amp; investigational products)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Conventional-treatment-resistant Pruritus in Patients Receiving Hemodialysis</condition>
  <arm_group>
    <arm_group_label>TRK-820 5μg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Taking TRK-820 5μg(two 2.5μg capsules) by oral route once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TRK-820 2.5μg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Taking TRK-820 2.5μg(one 2.5μg capsule &amp; one placebo capsule)by oral route once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Taking Placebo(two placebo capsule) by oral route once daily for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nalfurafine hydrochloride (TRK-820)</intervention_name>
    <description>Soft capsule containing 2.5ug nalfurafine hydrochloride. Start with 2.5ug of oral administraion once daily, and can be increased up to 5ug if necessary.</description>
    <arm_group_label>TRK-820 5μg</arm_group_label>
    <arm_group_label>TRK-820 2.5μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        [At the time of obtaining the consent form]

          -  Chronic renal failure patients who regularly receive hemodialysis three times a week
             and are not likely to have a serious treatment change or acute symptoms during the
             study period

          -  Patients who received both of the drug pruritus treatments in section 1 and 2 below
             within one year before the day of singing consent form

               1. Systemic therapy of more than two consecutive weeks depending on antihistamine or
                  antiallergic drugs falling under &quot;prescription drugs with indication of pruritus&quot;
                  (oral drugs, injections, etc.)

               2. Local therapy depending on &quot;prescription drugs with indication of pruritus&quot;
                  (ointment, etc.) or a moisturizer prescribed by a doctor (topical preparation,
                  etc.)

          -  Patients for whom all the conventional pruritus treatments in section (2) are not
             enough

          -  Patients aged 20 years or older at time of signing the consent form

        [At the time of enrollment]

          -  Patients whose VAS scores are measured both after breakfast and dinner for five days
             or more of the last 7 days of the predose observation period and whose mean of
             whichever the higher VAS scores after breakfast or dinner is ≥50 mm

          -  Patients whose whichever the higher VAS score after breakfast or dinner for the last 7
             days during the preliminary observation day (measured VAS score if one is missing) is
             more than ≥20 mm for five days or more

          -  Patients who are judged to have pruritus both during the day and at night for more
             than two days based on the Shiratori's severity criteria assessed by the subject at
             days of fifth and sixth hemodialysis and the day of hemodialysis after the completion
             of the predose observation period, and whose whichever the higher pruritis score
             measured during the day or at night is 3 (moderate) for two days or more

        Exclusion Criteria:

          -  Patients with malignant tumor

          -  Patients with depression, schizophrenia or dementia as complications

          -  Patients who currently have Child-pugh class B or C hepatic cirrhosis as complications

          -  Patients with clinically significant hepatic or cardiovascular diseases which cannot
             be controlled by diet or drug therapy

          -  Patients who currently have the following heart diseases: life-threatening arrhythmia;
             unstable angina or myocardiac infarction within 6 months; PCI or CABG within 6 months;
             NYHA class III or IV congestive heart failure

          -  Patients with atopic dermatitis or chronic urticaria as complications

          -  Patients who are allergic to opioid drugs

          -  Patients with dependence on drug or alcohol

          -  Patients who received phototherapy for pruritus within one month before signing the
             consent form

          -  Patients who participated in the study of TRK-820 and received the study drug or who
             were already enrolled in this study

          -  Patients who participated in other clinical studies (including the ones using
             artificial kidney and medical equipment), and received the study drug or treatment
             with clinical equipment within one month before signing the consent form

          -  Pregnant women, lactating women and patients of childbearing potential who do not use
             contraceptive methods

          -  Patients who cannot report VAS scores by their own for any reason at the principal
             investigator or study personnel's discretion

          -  Patients whose complications or history can impact the results of this study at the
             principal investigator or subinvestisator's discretion

          -  Other patients who are not proper to participate in this study at the principal
             investigator or study personnel's discretion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suhng Gwon Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SKchemicals Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2010</study_first_submitted>
  <study_first_submitted_qc>January 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2012</study_first_posted>
  <last_update_submitted>January 19, 2012</last_update_submitted>
  <last_update_submitted_qc>January 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pruritus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

